XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP) Stock Price, News & Analysis

Written before these shares stopped trading.

XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) represents a preferred equity security issued by XOMA Royalty Corporation, a biotechnology royalty aggregator. XOMA Royalty focuses on acquiring the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The Series A preferred stock is a distinct class of XOMA Royalty’s capital structure and trades separately from the company’s common stock under the symbol XOMA.

XOMA Royalty describes itself as playing a distinctive role in helping biotech companies pursue their goal of improving human health. When XOMA Royalty acquires future economic rights to a therapeutic candidate, the seller receives non-dilutive, non-recourse funding that can be used to advance internal drug candidates or for general corporate purposes. Over time, XOMA Royalty has built what it characterizes as an extensive and growing portfolio of assets, where each asset is defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate.

The XOMAP preferred shares are identified in XOMA Royalty’s SEC filings as 8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share, listed on The Nasdaq Global Market. The company has also issued depositary shares representing interests in a separate 8.375% Series B Cumulative Perpetual Preferred Stock, which trade under the symbol XOMAO. Both preferred series are referenced alongside the common stock in XOMA Royalty’s registration of securities under Section 12(b) of the Securities Exchange Act.

Business model of the issuing company

According to multiple company press releases, XOMA Royalty’s business model centers on acquiring milestone and royalty rights linked to therapeutic programs. These programs include both pre-commercial and commercial drug products that have been licensed to pharmaceutical or biotechnology partners. In exchange for transferring future economic rights, partners receive funding that does not dilute their equity and is non-recourse to them. XOMA Royalty’s portfolio includes commercial assets and a larger group of investigational compounds at various stages of development.

Company disclosures describe commercial assets in XOMA Royalty’s milestone and royalty portfolio as including VABYSMO (faricimab-svoa), OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate) vaginal gel 2%, IXINITY [coagulation factor IX (recombinant)], and DSUVIA (sufentanil sublingual tablet). All other assets in the portfolio are characterized as investigational compounds, for which efficacy and safety have not been established and which may not become commercially available.

Portfolio growth and transaction activity

Recent news releases highlight XOMA Royalty’s ongoing efforts to expand and diversify its royalty and milestone portfolio. The company has entered into and completed transactions to acquire economic interests in multiple biotechnology businesses and assets. Examples include the completed acquisitions of Turnstone Biologics and HilleVax, and the acquisitions of LAVA Therapeutics and Mural Oncology, which were described in company communications as expected or subsequently completed through tender offers or schemes of arrangement.

In addition to corporate acquisitions, XOMA Royalty has executed transactions that reshape its economic exposure to specific drug candidates. For instance, the company amended a long-standing collaboration with Takeda related to mezagitamab (TAK-079). Under the amended arrangement, Takeda’s royalty and milestone obligations to XOMA Royalty on mezagitamab are reduced, while XOMA Royalty becomes entitled to payments based on a share of milestones and royalties associated with nine development-stage assets in Takeda’s externalized assets portfolio. These assets include programs being developed by partners such as Neurocrine Biosciences, Mirum Pharmaceuticals, Oak Hill Bio, and Recursion Pharmaceuticals.

Role of preferred stock in the capital structure

XOMA Royalty’s Series A preferred stock (XOMAP) is one of the securities registered for trading on The Nasdaq Global Market, alongside the common stock and the Series B preferred depositary shares. Company press releases describe regular authorization of cash dividends to holders of the 8.625% Series A Cumulative Perpetual Preferred Stock and to holders of the Series B depositary shares. These disclosures underscore that the preferred shares are intended to provide recurring distributions, subject to authorization by the Board of Directors.

Because the Series A preferred stock is cumulative and perpetual, unpaid dividends accumulate according to the terms of the security, and the shares do not have a scheduled maturity date. The company’s periodic announcements of preferred dividends provide insight into how XOMA Royalty manages its obligations to preferred shareholders as it grows its royalty and milestone portfolio.

Corporate structure and listing information

According to XOMA Royalty’s Form 8-K filings, the company is incorporated in Nevada and its securities are registered under Commission File Number 001-39801. The filings list the following securities as trading on The Nasdaq Global Market: common stock under the symbol XOMA, 8.625% Series A Cumulative Perpetual Preferred Stock under the symbol XOMAP, and depositary shares representing interests in 8.375% Series B Cumulative Perpetual Preferred Stock under the symbol XOMAO.

The same filings identify XOMA Royalty’s principal executive offices as being located in Emeryville, California. The company’s disclosures emphasize its focus on acquiring milestone and royalty rights, structuring contingent value rights in connection with acquisitions, and maintaining a portfolio that spans commercial products and investigational drug candidates across multiple therapeutic areas.

Strategic focus and deal structuring

In public statements, XOMA Royalty’s leadership has highlighted a strategy that emphasizes disciplined capital deployment, detailed diligence, and deal structuring that often includes contingent value rights. These CVRs are designed to share in potential future proceeds from acquired programs, including partnered and unpartnered assets at acquisition targets such as LAVA Therapeutics and HilleVax. The company also reports that it sometimes acts as a structuring agent in third-party transactions, as illustrated by its role in XenoTherapeutics’ acquisition of ESSA Pharma.

By combining royalty acquisitions, corporate acquisitions, and structured transactions, XOMA Royalty seeks to build a diversified set of economic interests in therapeutic candidates at different stages of development. For investors in XOMAP, understanding the issuer’s approach to building and managing this portfolio can be an important part of evaluating the preferred stock’s risk and return characteristics.